Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial

Main Article Content

Bruce Strober
Joshua A. Zeichner
Seemal R. Desai
Michael Cameron
Jennifer Cather
Matthew J. Bruno
David S. Rubenstein
Anna Tallman
a:1:{s:5:"en_US";s:9:"Dermavant";}

Philip M. Brown

Keywords

Tapinarof, Aryl Hydrocarbon Receptor Agonist, Remittive Effect, Efficacy, Long-term Therapy, Plaque Psoriasis, Topical

References

1. Nowowiejska J, et al. Dermatol Ther (Heidelb). 2022;12:385–406.

2. Langley RGB, et al. Ann Rheum Dis. 2005;64(suppl 2):ii18–23.

3. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–67.

4. Tian D, Lai Y. J Invest Dermatol. 2022;2:100116. https://doi.org/10.1016/j.xjidi.2022.100116.

5. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432–70.

6. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed November 2022.

7. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–29.

8. Strober B, et al. J Am Acad Dermatol. 2022;87:800–6.

9. Fredriksson T, Pettersson U. Dermatologica. 1978;157:238–44.

10. Hongbo Y, et al. J Invest Dermatol. 2005;125:659–64.

11. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–21.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.125

Article Details

How to Cite
Strober, B., Zeichner, J. A. ., Desai, S. R. ., Cameron, M., Cather, J., Bruno, M. J., Rubenstein, D. S., Tallman, A. ., & Brown, P. M. (2023). Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial. SKIN The Journal of Cutaneous Medicine, 7(2), s125. https://doi.org/10.25251/skin.7.supp.125
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Posters from 2023 WCH Dermatology Conference: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>